Spyre Therapeutics (SYRE)Harwin Peter Evan disclosed a 10.0% stake in SYRE and may seek to influence the company 10.0%

10.0%

Stake

10.2M

Shares owned

Stake as of

Oct 7, 2026

Filed

Oct 9, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Sep 30, 2026InsiderCFO sold ~$1.57M of SYRE shares in the open market
2. Oct 1, 2026Insider · 3 peopleInsiders: 16 sales (~$4.7M)
3. Oct 5, 2026Company filing · Form 8-K · Material agreementSigned an important agreement

What came next

1. Oct 9, 20265% stakeHarwin Peter Evan filed an activist stake (13D) of 10.0%

How to read SEC Schedule 13D

A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.

Full guide: Schedule 13D vs Schedule 13G: what is the difference?

What else is on file for Spyre Therapeutics

For Spyre Therapeutics, OQRO holds 17 insider filings (SEC Form 4 or Form 144) and 9 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SYRE page.

How this filing works

• Schedule 13D vs 13G

Other disclosures at Spyre Therapeutics

• SEC Form 4Oct 3, 2026
• SEC Form 4Oct 3, 2026
• SEC Form 4Oct 3, 2026
• SEC Form 4Oct 3, 2026
• SEC Form 4Oct 3, 2026
• SEC Form 4Oct 3, 2026

Everything OQRO holds on this company is on its SYRE page.